


# Ultra CoQ10 CF



## CLINICAL APPLICATIONS

- Support Healthy Plasma/Tissue CoQ10 Levels Reduced by Aging & Clinical Conditions
- Support Health/Functioning of the Cardiovascular System
- Support Neuromuscular and Central Nervous System Health
- Support a Healthy Immune System
- Support Healthy Gums

*Ultra CoQ10 CF is an all-natural, proprietary, patent-pending, crystal/solvent-free, lipid-stabilized CoQ10 shown in recent clinical trials to be more than eight times as absorbable as powdered forms of CoQ10 and more than twice as bioavailable as oil-based or "nano" formulas. Ultra CoQ10 CF's proprietary monoglyceride carrier is a patent-pending formulation unmatched for optimal utilization in the support of cardiovascular, CNS, immune, and energy-based health needs.*

All 360° Medicine Formulas Meet or Exceed cGMP Quality Standards

## DISCUSSION

Coenzyme Q10 is a biologically active, natural vitamin-like substance belonging to a group of compounds called ubiquinones. Structurally similar to vitamin K, it is present in animal protein and can be synthesized in the body. However, a variety of factors, including aging, may cause a CoQ10 deficiency.

Despite its poor absorption (0.6-1.0%), pure crystalline (powdered) CoQ10 was the industry standard from the 1970's to the mid-1990's. A variety of forms and delivery systems offering somewhat improved absorption (2.3-5%) have entered the market since 1995; however, these forms have been unstable and crystallized, making them difficult or impossible for the body to absorb.

Ultra CoQ10 CF represents a new generation of CoQ10 supplements. Unlike many others in today's market place, it is crystal-free when examined by a light microscope. This patent-pending formulation contains three lipids to aid in dissolving CoQ10 crystals into single molecules, stabilizing the formula to prevent re-crystallization, and facilitating passive diffusion to enhance absorption.

A full double-blind, randomized clinical trial in twenty normal human volunteers with a relatively controlled diet was performed to determine the absorption and steady-state bioavailability characteristics. Absorption involves several phases in the movement of CoQ10 through a portion of the digestive tract, into the lymphatics, and into general circulation, where it becomes bioavailable. Absorption is reflected by the time base changes in the amount of CoQ10 appearing in the blood plasma after the ingestion of a single known dose. Bioavailability refers to the amount of CoQ10 accumulated in the blood plasma over an extended time after taking a known constant daily dose.

Within the trial, a 36-hour absorption study showed that Product Name had a total absorption 783% greater than powdered CoQ10 (11.65% vs 1.32%). The bioavailability study measured blood accumulation (mg) of CoQ10 over 28 days. The 28-day steady-state bioavailability for Ultra CoQ10 CF was 8.86 mg, compared to 1.64 mg for the dry powder standard. The relative bioavailability showed that Ultra CoQ10 CF was 541% more bioavailable than the standard product. The AUC (0-28 day) was 680 mg/day compared to 120 mg/day or 463% more bioavailable than the dry powder standard.

Ultra CoQ10 CF is titanium dioxide-free, making the softgel transparent and permitting verification of the crystal-free claim.

RUSS CANFIELD, MD  
505.795.7111

66 AVENIDA ALDEA  
SANTA FE, NM 87507

# Ultra CoQ10 CF



## Supplement Facts

Serving Size: 1 Softgel  
Servings Per Container: 60

	Amount Per Serving	%Daily Value
CoQ10 (ubiquinone)	100 mg	**

\*\* Daily Value not established.

**Other Ingredients:** Conjugated linoleic acid, flaxeed oil, gelatin, monoglyceride, glycerin and water.

## DOSAGE:

Take one to two softgels daily, with meals, or as directed by your healthcare practitioner.

## REFERENCES

- Berthold HK, et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomized trial. *Drug Saf.* 2006;29(8):703-12 [PMID: 16872244]
- Lopez-Lluch G, Barroso MP, Martin SF, Fernandez-Ayala DJ, Gomez-Diaz C, Villalba JM, Navas P. Role of plasma membrane coenzyme Q on the regulation of apoptosis. *Biofactors.* 1999;9(2-4):171 [PMID: 10416029]
- Crane FL Biochemical functions of coenzyme Q10. *J Am Coll Nutr.* 2001 Dec;20(6):591-8
- Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. *Arch Neurol.* 2004 Jun;61(6):889-92 [PMID: 15210526]
- Littarru GP, Lippa S, Oradei A, Serino F. Coenzyme Q10: blood levels and metabolic demand. *Int J Tissue React.* 1990;12(3):145-8. [PMID: 2276891]
- Munkholm H, Hansen HHT, Rasmussen K: Coenzyme Q10 treatment in serious heart failure. *Biofactors* 1999;9(2-4): 285-289 [PMID: 10416042]
- Eriksson JG, Forsen TJ, Mortensen SA, Rohde M: The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. *Biofactors* 1999: 315-318 [PMID: 10416046]
- Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. *Biofactors.* 1999; 9(2-4): 273-84. [PMID:10416041]
- Rosenfeldt F, Hilton D, Pepe S, Krum H Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. *Biofactors.* 2003;18(1-4):91-100 [PMID: 14695924]
- Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. *Curr Opin Clin Nutr Metab Care.* 2005 Nov;8(6):641-6. Review. [PMID: 16205466]
- de Lau LM. Serum cholesterol levels and the risk of Parkinson's disease. *Am J Epidemiol.* 2006 Nov 15;164(10):998-1002. Epub 2006 Aug [PMID: 16905642]
- Figuero E, et al. Oxidant/antioxidant interactions of nicotine, Coenzyme Q10, Pycnogenol and phytoestrogens in oral periosteal fibroblasts and MG63 osteoblasts. *Steroids.* 2006 Dec;71(13-14):1062-72. Epub 2006 Oct 11 [PMID: 17045317]

## CAUTION:

Consult with your healthcare practitioner before use. Keep out of reach of children.

\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.



# 360° Medicine

DRS-228  
REV. 04/25/11